Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intelgenx Technologies Corp (OP: IGXT )

N/A UNCHANGED
Last Price Updated: 3:57 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intelgenx Technologies Corp

< Previous 1 2 3 4 Next >
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q1 2024
Intelgenx Technologies just reported results for the first quarter of 2024. 
Via InvestorPlace
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023
Intelgenx Technologies just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?
IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the... 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
FDA Gives Nod To IntelGenx's Migraine Solution As Revenues Plunge 32%; Q1 Results Report
IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same 
Via Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... 
Via Benzinga
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?
Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show: 
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
Via Benzinga
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche 
Via Benzinga
IntelGenx Reports Q3 2022 Financial Results, Management Anticipates Psychedelics Trials In 2023
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) reported its financial results late Thursday for the third quarter that ended September 30, 2022. 
Via Benzinga
New Oral Film Tech Improving Cannabinoid Onset Seeks Patent Protection
Pharmaceutical films leader IntelGenx Corp. (OTCQB: IGXT) filed a provisional patent application with the U.S. 
Via Benzinga
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
Drug delivery company IntelGenx Corp. 
Via Benzinga
Short Volatility Alert: IntelGenx Technologies Corp.
On Monday, shares of IntelGenx Technologies Corp. (OTC: IGXT) experienced volatile short activity. After the activity, the stock price went up +7.69% to $0.13. The overall sentiment for IGXT has been... 
Via Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 4.95% at $0.34 
Via Benzinga
Psychedelic Stock Gainers And Losers From July 29, 2022
GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 11.30% at $0.22 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13 
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72 
Via Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 3, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.